The FDA's drug database lists a supplement dated 8 October 2026 to an abbreviated new drug application for tafluprost held by Micro Labs. The record names only the application, the company and the drug.
It does not say what the supplement changed, and supplements can cover manufacturing, labelling or other administrative matters. Tafluprost is a prostaglandin analogue used to lower intraocular pressure.
There is no safety finding here, and the record does not show a new indication. The CDSCO status and availability of this generic in India are not stated in the notice.
- No action is needed for patients on tafluprost on the basis of this record.
- Check labelling updates from your supplier if you stock this product.
- Continue to monitor intraocular pressure as usual.
- Report suspected adverse reactions through your local pharmacovigilance route.
Why it matters
Regulatory entries are often administrative, and it is useful to know when one is not a safety signal.
Don't overread it
A supplement to a generic application is not a new indication or a safety finding, and the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free